Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Congo

Clinical Infectious Diseases

Volumn 45, Issue 11, 2007, Pages 1435-1442

  Priotto, Gerardo ^a   Kasparian, Serena ^a   Ngouama, Daniel ^b   Ghorashian, Sara ^c   Arnold, Ute ^c   Ghabri, Salah ^a   Karunakara, Unni ^c  

^a EPICENTRE   (France)

^b Ministry of Health   (Congo)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; NIFURTIMOX; ANTITRYPANOSOMAL AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AFRICAN TRYPANOSOMIASIS; AGED; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONFUSION; CONGO; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEATH; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEIZURE; SEPTIC SHOCK; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; TRYPANOSOMA; WEIGHT REDUCTION; ANIMAL; DRUG COMBINATION; MIDDLE AGED; PARASITOLOGY;

ADOLESCENT; ADULT; AGED; ANIMALS; CONGO; DRUG THERAPY, COMBINATION; EFLORNITHINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NIFURTIMOX; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 38449084743     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522982     Document Type: Article

References (26)

1. World Health Organization. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol Rec 2006; 81:71-80. Available at: http://www.who.int/wer/2006/wer8108.pdf.
2. Pepin J, Milord F, Khonde AN, et al. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995; 89:92-7.
3. World Health Organization. Control and surveillance of African trypanosomiasis: report of a WHO expert committee. WHO technical report series 881. Geneva: World Health Organization, 1998.
4. Burri C, Keiser J. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health 2001; 6:412-20.
5. Legros D, Evans S, Maiso F, Enyaru JC, Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999; 93:439-42.
6. Stanghellini A, Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 2001; 6:330-4.
7. Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by substrate and product analogues. J Am Chem Soc 1978; 100:2551-3.
8. Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 1980; 210:332-4.
9. Bacchi CJ, Garofalo J, Mockenhaupt D, et al. In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei. Mol Biochem Parasitol 1983; 7:209-25.
10. Abeloff MD, Slavik M, Luk GD, et al. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine - an inhibitor of polyamine biosynthesis. J Clin Oncol 1984; 2:124-30.
11. Griffin CA, Slavik M, Chien SC, et al. Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine. Invest New Drugs 1987; 5:177-86.
12. Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972; 22:1624-35.
13. Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection: preliminary report. Arzneimittelforschung 1972; 22:1635-41.
14. Janssens PG, De Muynck A. Clinical trials with "nifurtimox" in African trypanosomiasis. Ann Soc Belg Med Trop 1977; 57:475-80.
15. Pepin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 1992; 86:254-6.
16. Moens F, De Wilde M, Ngato K. [Clinical trial of nifurtimox in human African trypanosomiasis]. Ann Soc Belg Med Trop 1984; 64:37-43.
17. Van Nieuwenhove S. Advances in sleeping sickness therapy. Ann Soc Belg Med Trop 1992; 72(Suppl 1):39-51.
18. Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 2006; 1:e39.
19. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Neglected Trop Dis (in press).
20. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355:1419-25.
21. Pepin J, Khonde N, Maiso F, et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ 2000; 78:1284-95.
22. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 2004; 364:789-90.
23. Lejon V, Buscher P, Sema NH, Magnus E, Van Meirvenne N. Human African trypanosomiasis: a latex agglutination field test for quantifying IgM in cerebrospinal fluid. Bull World Health Organ 1998; 76:553-8.
24. Bailey JW, Smith DH. The use of the acridine orange QBC technique in the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg 1992; 86:630.
25. National Cancer Institute, National Institutes of Health. Cancer therapy evaluation program: common toxicity criteria, version 2.0. 1999. Available at: http://ctep.cancer.gov/forms. Accessed 21 May 2007
26. Iten M, Mett H, Evans A, Enyaru JC, Brun R, Kaminsky R. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrob Agents Chemother 1997; 41:1922-5.